Quanterix Reports Q3 Revenue of $40.2 Million
Quanterix Corporation reported third quarter 2025 revenue of $40.2 million, up 12.3% from $35.8 million in the prior year. GAAP gross margin was 42.8%, down from 56.3% the previous year, while adjusted gross margin (non-GAAP) was 45.9%, compared to 50.7%. The company reported an adjusted EBITDA (non-GAAP) loss of $11.9 million, compared to a loss of $5.5 million last year, mainly due to higher acquisition and restructuring charges. Cash, cash equivalents, marketable securities, and restricted cash totaled $138.1 million at quarter end. Adjusted cash usage for the quarter was $16.1 million, with expectations to end 2025 with approximately $120 million in cash and equivalents. Quanterix reiterated full-year 2025 revenue guidance of $130 to $135 million, or $165 to $170 million on a pro forma basis. The company expects to achieve $85 million in annualized synergies from the Akoya integration and reach cash flow breakeven in 2026. Business highlights include the integration of Akoya operations and sales teams, and progress in the Alzheimer's diagnostics segment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110450301) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.